Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 9/20 | 0.48 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833337 | 0.92 | RXFP1 (0.45) | NR1H4PPARGPPARAPPARDNLRP3 | |
| SCHEMBL6834072 | 0.92 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL6834504 | 0.91 | LMNA (0.47) | ALDH1A1 | |
| SCHEMBL6833766 | 0.90 | PARP14 (0.43) | NR1H4PPARGPPARAPPARDSERPINE1 | |
| SCHEMBL6834079 | 0.90 | NHERF1 (0.44) | SERPINE1ALDH1A1 | |
| SCHEMBL6835671 | 0.90 | LMNA (0.39) | — | |
| SCHEMBL6834134 | 0.89 | IDO1 (0.43) | NR1H4NLRP3CACNA1HALDH1A1 | |
| SCHEMBL6834350 | 0.89 | ALDH1A1 (0.50) | PPARDNLRP3HCAR2ALDH1A1 | |
| SCHEMBL6833113 | 0.89 | SMN1; SMN2 (0.46) | NLRP3ALDH1A1 | |
| SCHEMBL6834298 | 0.88 | MEN1 (0.44) | NR1H4PPARGPPARAPPARDNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | NR1H4 1201/4885PPARG 285/4885PPARA 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.